No Data
No Data
Qianjiang Yongan Pharmaceutical's (SZSE:002365) Five-year Decline in Earnings Translates Into Losses for Shareholders
This week we saw the Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) share price climb by 19%. But that doesn't change the fact that the returns over the last five years have been less than
Yongan Pharmaceutical (002365.SZ): Net profit of 28.68 million yuan in the first quarter increased 91.42% year-on-year
On April 29, Ge Longhui | Yongan Pharmaceutical (002365.SZ) released its first quarter report. Operating revenue was 197 million yuan, down 36.80% year on year, net profit of 28.68 million yuan, up 91.42% year on year, after deducting non-net profit of 1997 million yuan, up 247.61% year on year, with basic earnings of 0.0973 yuan per share.
Yongan Pharmaceutical (002365.SZ) has been re-certified as a high-tech enterprise
Gelonghui, April 23 | Yongan Pharmaceutical (002365.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Hubei Provincial Department of Science and Technology, the Hubei Provincial Department of Finance, and the Hubei Provincial Taxation Bureau of the State Administration of Taxation, and the company passed the new certification as a high-tech enterprise. The certificate number is GR202342010015, the date of issue is October 26, 2023, and is valid for three years.
Yongan Pharmaceutical (002365.SZ) announced its 2023 annual results, changing from profit to loss of RMB 12.312,600
Yongan Pharmaceutical (002365.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
Yongan Pharmaceutical (002365.SZ): The main product taurine has a wide range of applications and has been used in cosmetics
Gelonghui, Feb. 22 | Yongan Pharmaceutical (002365.SZ) said on the investor interactive platform that the company and its subsidiaries are mainly engaged in four types of business, one is R&D, production and sales of taurine products; the second is the production and sale of ethylene oxide and R&D, production and sales of related products such as polycarboxylic acid water reducing agent monomers, water reducing agents, etc.; the third is health food R&D, production and sales, and foreign health food imports and sales; four is equity or industrial investment related to the health sector, and the use of some idle funds for cash management, etc. The company's main product, taurine, has a wide range of applications and has been used in cosmetics;
Yongan Pharmaceutical (002365.SZ): As of February 8, 2024, the number of shareholders of the company was 26,645
Gelonghui February 22丨Yongan Pharmaceutical (002365.SZ) said on the investor interactive platform that as of February 8, 2024, the number of shareholders of the company was 26,645.
No Data